Skip to content
akaturk Academic measurement

Article detail · 2021 · article

Flavonoids against the SARS-CoV-2 induced inflammatory storm

ISSN0753-3322
YÖKSİS OpenAlex Open access · gold SJR Q1 JCR Q1 Top 10%
Year2021
Citations147OpenAlex
Percentile%98.1
FWCI8.151.00 = world average
Scopus (SJR)Q1
WoS (JCR)Q1

Data source split

  • YÖKSİSYÖKSİS article record
  • YÖKSİS venueBiomedicine & Pharmacotherapy
  • Catalog match (ISSN)Biomedicine and Pharmacotherapy
  • OpenAlexOpenAlex enrichment (abstract, citations, topics)

Abstract

OpenAlex English

The disease severity of COVID-19, especially in the elderly and patients with co-morbidities, is characterized by hypercytokinemia, an exaggerated immune response associated with an uncontrolled and excessive release of proinflammatory cytokine mediators (cytokine storm). Flavonoids, important secondary metabolites of plants, have long been studied as therapeutic interventions in inflammatory diseases due to their cytokine-modulatory effects. In this review, we discuss the potential role of flavonoids in the modulation of signaling pathways that are crucial for COVID-19 disease, particularly those related to inflammation and immunity. The immunomodulatory ability of flavonoids, carried out by the regulation of inflammatory mediators, the inhibition of endothelial activation, NLRP3 inflammasome, toll-like receptors (TLRs) or bromodomain containing protein 4 (BRD4), and the activation of the nuclear factor erythroid-derived 2-related factor 2 (Nrf2), might be beneficial in regulating the cytokine storm during SARS-CoV-2 infection. Moreover, the ability of flavonoids to inhibit dipeptidyl peptidase 4 (DPP4), neutralize 3-chymotrypsin-like protease (3CLpro) or to affect gut microbiota to maintain immune response, and the dual action of angiotensin-converting enzyme 2 (ACE-2) may potentially also be applied to the exaggerated inflammatory responses induced by SARS-CoV-2. Based on the previously proven effects of flavonoids in other diseases or on the basis of newly published studies associated with COVID-19 (bioinformatics, molecular docking), it is reasonable to assume positive effects of flavonoids on inflammatory changes associated with COVID-19. This review highlights the current state of knowledge of the utility of flavonoids in the management of COVID-19 and also points to the multiple biological effects of flavonoids on signaling pathways associated with the inflammation processes that are deregulated in the pathology induced by SARS-CoV-2. The identification of agents, including naturally occurring substances such as flavonoids, represents great approach potentially utilizable in the management of COVID-19. Although not clinically investigated yet, the applicability of flavonoids against COVID-19 could be a promising strategy due to a broad spectrum of their biological activities.

Topics

Citations

OpenAlex cited_by_count. Not a WoS or Scopus citation count; those sources have no separate column here.

147citationsOpenAlex · cited_by_count (cache / database)

10 publications in the local catalog that cite this work (OpenAlex reference match; not the full global list).

  1. 2021 Inhibitory effects of sulforaphane on NLRP3 inflammasome activationCitations 54 · OpenAlex
  2. 2022 Some flavolignans as potent SARS-CoV-2 inhibitors via molecular docking, molecular dynamic simulations and ADME AnalysisCitations 27 · OpenAlex
  3. 2023 Natural Products as a Potential Source of Promising Therapeutics for COVID-19 and Viral DiseasesCitations 13 · OpenAlex
  4. 2023 In vitro evaluation of 2-pyrazoline derivatives as DPP-4 inhibitorsCitations 5 · OpenAlex
  5. 2023 In vitro evaluation of 2-pyrazoline derivatives as DPP-4 inhibitorsCitations 5 · OpenAlex
  6. 2023 In vitro evaluation of 2-pyrazoline derivatives as DPP-4 inhibitorsCitations 5 · OpenAlex
  7. 2023 In vitro evaluation of 2-pyrazoline derivatives as DPP-4 inhibitorsCitations 5 · OpenAlex
  8. 2022 Preclinical toxicity test results of a new antiviral–immune-modulator compound consisting of flavonoid molecules (COVID-19 clinical trial preliminary data)Citations 2 · OpenAlex
  9. 2022 Preclinical toxicity test results of a new antiviral–immune-modulator compound consisting of flavonoid molecules (COVID-19 clinical trial preliminary data)Citations 2 · OpenAlex
  10. 2021 Preclinical toxicity test results of a new antiviral–immune-modulator compound consisting of flavonoid molecules (COVID-19 clinical trial preliminary data)Citations 0 · OpenAlex

Authors

1
  1. ALI ZARRABI İSTİNYE ÜNİVERSİTESİ 1